



A New Wave: Emerging Therapies in the Atopic Dermatitis Pipeline

Generic drug name	Drug Class	Route of Administration	Phase of Development	Age Group Being Studied	Company
Dupilumab*	IL-4/IL-13 inhibitor	subcutaneous injection	Phase 3	Ages 6 months+	Regeneron-Sanofi
Ruxolitinib*	JAK1/2 inhibitor	topical cream	Phase 3	Ages 2–11	Incyte
Tralokinumab*	IL-13 inhibitor	subcutaneous injection	Phase 3	Ages 12+	LEO Pharma
Upadacitinib	JAK1 inhibitor	oral	Phase 3	Ages 12+	AbbVie
Abrocitinib	JAK1 inhibitor	oral	Phase 3	Ages 12+	Pfizer
Baricitinib	JAK1/2 inhibitor	oral	Phase 3	Ages 2–7	Eli Lilly and Company
Nemolizumab	IL-31 inhibitor	subcutaneous injection	Phase 3	Ages 12+	Galderma
Lebrikizumab	IL-13 inhibitor	subcutaneous injection	Phase 3	Ages 12+	Eli Lilly/Dermira
Tapinarof	AhR inhibitor	topical	Phase 3	Ages 2+	Dermavant
Roflumilast	PDE4 inhibitor	topical	Phase 3	Ages 2-5	Arcutis
ATI-1777	JAK1/3 inhibitor	topical	Phase 2 (Completed)	Ages 18+	Aclaris Therapeutics
Delgocitinib	JAK inhibitor	topical	Phase 2 (Completed)	Ages 18+	LEO Pharma
Bermekimab	IL-1 α inhibitor	subcutaneous injection	Phase 2	Ages 18+	Janssen
Benralizumab	IL-5 inhibitor	subcutaneous injection	Phase 2	Ages 12+	AstraZeneca

*Approved by the FDA for use in a different patient age range